Calocurb is the world's first patented GLP-1 activator.
We have the science and global recognition to prove it
Calocurb's journey began with the groundbreaking discovery of Amarasate® in 2013, emerging from over ten years of meticulous research by the New Zealand Institute for Plant and Food Research Limited, a New Zealand government-owned Crown Research Institute. Supported by NZD $20 million of funding from the Ministry of Business, Innovation, and Employment (MBIE), this extensive investigation found Amarasate® , a bitter extract from a specific variety of NZ hop flower - identified as having the ability to activate the body’s natural feeling of fullness and satiety.
The effectiveness and potency of the bitterness of Amarasate® has been demonstrated superior to over 900 plants and pharmaceutical products when delivered to the small intestine to trigger appetite-suppression.
The Perfect Capsule
Our acid-resistant vegetarian capsules ensure that Calocurb releases the power of bitterness at just the right spot of the small intestine, specifically the duodenum. Designed by the world-leading Capsugel team, our clever capsules are the epitome of science and innovation, allowing Calocurb to start working in just one hour.
The power of science and nature - Amarasate® mode of action
After only one hour, Amarasate® stimulates the bitter taste receptors (TAS2R) receptors found on enteroendocrine cells to release gastric hormones (GLP-1 and CCK) at 6 times baseline levels, twice the normal post-prandial release. Overall, the main satiety hormones (GLP-1, CCK and PYY) feature enhanced release with the activation of TAS2R along the small intestine.
These gastric hormones signal a part of the brain to decrease appetite and food cravings plus slow down the gastric emptying rate.
This is clinically shown to;
- Reduce caloric intake by an average of 18%
- Reduce changes in hunger by up to 100%
- Reduce changes in cravings by up to 120%
Due to the delayed release of Calocurb into the small intestine, over 99% of Amarasate® is metabolized in the large colon, bypassing the entrance into the bloodstream or hepatic system.